Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179631 · ClinicalTrials.gov registry record · Phase 3
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
A Phase 3 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT03179631 is a Phase 3 study that has completed, run by PTC Therapeutics. The registered enrollment target is 360 participants.
The verdict
NCT03179631, a Phase 3 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
Interventions
- DRUG PLACEBO
- DRUG Ataluren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179631
The ClinicalTrials.gov registry entry for NCT03179631 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT03179631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179631 about?
NCT03179631 is a clinical study titled "Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy". This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
What is the current status of trial NCT03179631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2017-07-06. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT03179631?
The interventions under investigation include: PLACEBO (DRUG), Ataluren (DRUG).
Who is sponsoring clinical trial NCT03179631?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.